Avascular Necrosis Market, By Drug Type, By Route of Administration, By Distribution Channel, By Geography

Description

Avascular Necrosis Market is estimated to be valued at USD 809.5 Mn in 2026 and is expected to reach USD 1,216.9 Mn by 2033, growing at a compound annual growth rate (CAGR) of 6.0% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 809.5 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	6.00%	2033 Value Projection:	USD 1,216.9 Mn

Avascular necrosis is a disease that results from the short-term or permanent loss of blood supply to the bone. This cut-off of blood supply to bone leads to tiny breaks in the bone and the bones eventually collapse. Avascular necrosis is also known as osteonecrosis. This condition may happen in any bone of the body, but mostly happens in the ends of a long bone. A broken bone or dislocated joint can interrupt the blood flow to a section of bone. Avascular necrosis condition is most common in people between the ages of 30 and 50.

Avascular necrosis can be caused due to-

Injury to bone
Fracture
Damage of blood vessels
Long-term use of medicines, such as corticosteroids
Excessive, long-term use of alcohol

Avascular necrosis can be diagnosed by Bone scan, Magnetic Resonance Image and Computed Tomography, and X-rays. Medications used to treat avascular necrosis are blood thinners, nonsteroidal anti-inflammatory drugs, cholesterol lowering drugs and others.

Market Dynamics

Increasing number of product launches is expected to drive the growth of global avascular necrosis market during the forecast period. For instance, in September 2014, Bayer Healthcare LLC, a pharmaceutical and medicine manufacturing company, announced the launch of Aleve PM, an over-the-counter (OTC) pain reliever product in the U.S.

Increasing number of drug approvals from regulatory bodies is expected to drive the growth of the global avascular necrosis market. For instance, in April 2019, the U.S Food and Drugs Administration approved Evenity (romosozumab-aqqg), a sclerostin inhibitor indicated to treat osteoporosis in postmenopausal women at high risk of breaking a bone.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global avascular necrosis market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Solara Active Pharma Sciences Limited., Bayer AG, Rochem International, Inc., Alkem Labs., Dwarkesh Pharmaceuticals Private Limited., Novartis AG, GSK, and Pfizer Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global avascular necrosis market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global avascular necrosis market

Market Segmentation

By Drug Type Insights (Revenue, USD Mn, 2021 - 2033)
Nonsteroidal anti-inflammatory drugs (Ibuprofen, Naproxen Sodium)
Osteoporosis Drugs
Cholesterol-lowering Drugs
Blood Thinners
Others
By Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
Oral
Injectable
By Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region Insights (Revenue, USD Mn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- North Africa
- South Africa
- Central Africa
Key Players in the Avascular Necrosis Market
Teva Pharmaceutical Industries Ltd.
Reddy's Laboratories Ltd.
Solara Active Pharma Sciences Limited
Bayer AG
Rochem International Inc.
Alkem labs.
Dwarkesh Pharmaceuticals Private Limited.
Novartis AG
GSK
Pfizer, Inc.

Product Code: CMI2218

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Route of Administration
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Market Opportunities
Impact Analysis
Market Trends
Recent Product Launches/Approvals
Regulatory Scenario
Epidemiology
PEST Analysis
Acquisition and Collaboration Scenario

4. Global Avascular Necrosis Market, By Drug Type, 2021 - 2033 (USD Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Nonsteroidal anti-inflammatory drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
  - Ibuprofen
  - Naproxen Sodium
Osteoporosis drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
Cholesterol-lowering drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
Blood Thinners
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)

5. Global Avascular Necrosis Market, By Route of Administration, 2021 - 2033 (USD Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)

6. Global Avascular Necrosis Market, By Distribution Channel, 2021 - 2033, (USD Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)

7. Global Avascular Necrosis Market, By Region, 2021 - 2033, (USD Million)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, By Region, 2022 - 2033
- Regional Trends
North America
- Market Size and Forecast, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Route of Administration 2021 - 2033, (USD Million)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
  - U.S.
  - Canada
Europe
- Market Size and Forecast, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Route of Administration 2021 - 2033, (USD Million)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Route of Administration 2021 - 2033, (USD Million)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
  - China
  - Japan
  - India
  - ASEAN
  - Australia
  - South Korea
  - Rest of APAC
Latin America
- Market Size and Forecast, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Route of Administration 2021 - 2033, (USD Million)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Market Size and Forecast, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Route of Administration 2021 - 2033, (USD Million)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Size and Forecast, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Route of Administration 2021 - 2033, (USD Million)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Company Profiles
- Teva Pharmaceuticals Industries Ltd.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Dr. Reddy's Laboratories Ltd.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Solara Active Pharma Sciences Limited.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Bayer AG
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Rochem International, Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Alkem Labs.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Dwarkesh Pharmaceuticals Private Limited
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Novartis AG
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- GSK
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Pfizer, Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies

9. Section

References
Research Methodology
About us and Sales Contact